Division of Colorectal Surgery, Shizuoka Cancer Center Hospital, Nagaizumi-cho, Japan.
Dig Surg. 2013;30(4-6):272-7. doi: 10.1159/000354034. Epub 2013 Aug 20.
The purpose of this study was to assess the feasibility of laparoscopic intersphincteric resection (LAP-ISR) for rectal cancer in terms of morbidity, oncological outcomes, and functional results.
Thirty-seven patients with primary low rectal cancer cT1-T2 underwent LAP-ISR. Surgical outcomes, pathological results, postoperative complications, oncological outcomes, and functional results were analyzed retrospectively.
Three patients (8.1%) had carcinoma in situ, 22 (59.5%) had pT1 tumor, and 11 (29.7%) had pT2 tumor. Eleven patients (29.7%) were diagnosed as being node positive, while 26 (70.3%) had node-negative disease. The median operative time was 315 min (range: 195-502). The median blood loss was 37 ml (range: 0-745). One case was converted to open surgery. Pathological complete resection was achieved in all cases. There was no surgical mortality. Postoperative complications of grade III-IV on the Clavien-Dindo classification were observed in 16.2% of the patients. The median follow-up period was 2.8 years (range: 187-2,241 days), and 3-year disease-free survival was 93.1%. No patient developed local recurrence. The functional result was objectively good.
LAP-ISR can be recommended as a feasible, ultimate sphincter-preserving procedure with acceptable functional and intermediate-term oncological outcomes in patients with cT1-T2 very low rectal cancer.
本研究旨在评估经肛门内括约肌切除术(LAP-ISR)治疗低位直肠癌的可行性,包括发病率、肿瘤学结果和功能结果。
37 例原发性低位直肠癌 cT1-T2 患者接受 LAP-ISR 治疗。回顾性分析手术结果、病理结果、术后并发症、肿瘤学结果和功能结果。
3 例(8.1%)患者为原位癌,22 例(59.5%)为 pT1 肿瘤,11 例(29.7%)为 pT2 肿瘤。11 例(29.7%)患者诊断为淋巴结阳性,26 例(70.3%)为淋巴结阴性。中位手术时间为 315 分钟(范围:195-502 分钟)。中位出血量为 37 毫升(范围:0-745 毫升)。1 例中转开腹手术。所有病例均达到病理完全切除。无手术死亡病例。术后并发症按 Clavien-Dindo 分级为 III-IV 级者占 16.2%。中位随访时间为 2.8 年(范围:187-2241 天),3 年无病生存率为 93.1%。无患者发生局部复发。功能结果客观良好。
LAP-ISR 可作为一种可行的、终极的保留括约肌手术方法,适用于 cT1-T2 低位直肠癌患者,具有可接受的功能和中期肿瘤学结果。